175 related articles for article (PubMed ID: 25605745)
1. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
4. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
6. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.
Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
Leuk Lymphoma; 2007 Aug; 48(8):1539-47. PubMed ID: 17701585
[TBL] [Abstract][Full Text] [Related]
10. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
[TBL] [Abstract][Full Text] [Related]
12. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
[TBL] [Abstract][Full Text] [Related]
13. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
14. Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
Tomita N; Hattori Y; Fujisawa S; Hashimoto C; Taguchi J; Takasaki H; Sakai R; Tateishi U; Ishigatsubo Y
Ann Hematol; 2015 Mar; 94(3):431-6. PubMed ID: 25338967
[TBL] [Abstract][Full Text] [Related]
15. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822
[TBL] [Abstract][Full Text] [Related]
16. Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma.
Gurion R; Bernstine H; Domachevsky L; Michelson C; Raanani P; Vidal L; Shochat T; Gafter-Gvili A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):687-691. PubMed ID: 30017596
[TBL] [Abstract][Full Text] [Related]
17. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
[TBL] [Abstract][Full Text] [Related]
19. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
